LY3885125
Phase 1Small molecule
Eli LillyLY3885125 is one of 38 small molecule programs targeting Non-Alcoholic Fatty Liver Disease. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
101 competitors in Non-Alcoholic Fatty Liver Disease
#DrugCompanyPhaseTrials
1Aquasol E
NNational Eye Institute (NEI)
Phase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Rezdiffra
Madrigal PharmaceuticalsPhase 3
Omacor
AstraZenecaPhase 3
Lipaglyn
ZZydus Therapeutics Inc.
Phase 3
Precose
BayerPhase 2
Byetta
AstraZenecaPhase 2
Investigational Treatment
NovartisPhase 3
Glucophage
EMD SeronoPhase 2
Ocaliva
IIntercept Pharmaceuticals
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LY3885125. EMBL-EBI & Wellcome Sanger Institute.
- [4]